Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FDA, FVT

Mesa Biotech to Present Comparative Flu & RSV Detection Analysis with Other FDA-Cleared Molecular Assays at the AACC Annual Scientific Meeting Lecture Series


SAN DIEGO, July 31, 2019 /PRNewswire/ -- Mesa Biotech Inc. is a privately-held, molecular diagnostic company that has developed the Acculatm System, an affordable, sample-to-answer, CLIA-waived PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis. Today, Mesa Biotech announced it will present performance comparisons of its visually read PCR testing platform with other FDA-cleared molecular tests for influenza A/B and respiratory syncytial virus (RSV) assays. The lecture will take place on August 6, 2019 at 1:00 pm in theater 3 of the exhibit hall at the 71st American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo in Anaheim, CA. Additionally, the Accula System's RSV and Flu A/Flu B molecular tests will be on exhibit in Booth 3902 at AACC.

(PRNewsfoto/Mesa Biotech Inc.)

"Antiviral drug treatments are becoming increasingly popular and more widely used. The antivirals work best when taken within 48 hours of symptom onset, therefore highly accurate, POC testing is crucial for healthcare professionals to achieve rapid and accurate confirmation of the infection to enable the best patient outcome," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc.

Stephen Young, PH.D., Director of Research and Clinical Trials at TriCore Reference Laboratory will present the session titled 'Sample-to-answer, CLIA-waived PCR System with Visually Read Results for POC: Comparative Flu and RSV Detection Analysis with Other FDA-cleared Molecular POC Assays'. The presentation will provide a technology overview and performance characteristics of the visually interpreted, CLIA-waived Accula System that possesses the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassays. Additionally, Dr. Young will provide insight on the user experience with the Accula System.

About Mesa Biotech Inc.
Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care (POC). Mesa Biotech's Acculatm System consists of a portable, palm-sized dock and single-use, assay-specific test cassettes. This patented system enables healthcare professionals to access actionable, laboratory-quality results at the POC with greater sensitivity and specificity than current infectious disease rapid immunoassay tests. The Accula Flu A/Flu B and the Accula RSV tests have obtained CE Mark in the EU and 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA). Both products are distributed in the US by Sekisui Diagnostics under the Silaristm brand. Mesa Biotech has also secured a number of strategic agreements for distribution in Europe and Asia.  For more information visit http://www.mesabiotech.com.

 

 

 

 

SOURCE Mesa Biotech Inc.


These press releases may also interest you

at 20:05
Process Systems Enterprise (PSE), the leading supplier of Advanced Process Modelling (APM) software and services, today announced that it plans to be acquired by Siemens AG in a transaction scheduled to close in Q4 2019. The 160-strong PSE operation...

at 19:35
AVITA Medical , a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a patient's own skin, announced today that the U.S. Food and Drug Administration (FDA) has...

at 19:15
The "Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases" report has been added to ResearchAndMarkets.com's offering. This report evaluates the landscape of investigational bispecific therapeutic antibodies for treatment...

at 19:14
How does Phoenix, Ariz. maintain the title of being the "most autism friendly city" in the world? To answer that question, you need to explore the constantly expanding Arizona network of autism resources and organizations dedicated to helping those...

at 18:47
Today at the Heart Failure Society of America Annual Meeting Dr. William T. Abraham the SMILE national principle investigator presented the results of the study as a late breaking trial. The study examined use of ReDStm non-invasive remote monitoring...

at 18:44
Softheon, a national leader in cloud-based health insurance exchange integration, announced today that the Centers for Medicare & Medicaid Services (CMS) approved them as one of the leading Phase 3 Enhanced Direct Enrollment (EDE) vendors. Softheon's...



News published on 31 july 2019 at 07:30 and distributed by: